Here are three things to know.
1. Viralytics, a Sydney, Australia-based biotech company, uses viruses to detect and kill cancer cells.
2. Under the terms of the deal, Merck will pay 1.75 Australian dollars ($1.37) per share for the company.
3. “We are eager to further build on Viralytics’s science as we continue our efforts to harness the immune system to improve long-term disease control and survival outcomes for people with cancer,” Roy Baynes, MD, PhD, senior vice president and head of global clinical development, CMO of Merck Research Laboratories, said in a press release.
More articles on supply chain:
Amazon quietly launches exclusive OTC product line: 7 things to know
AbbVie, Voyager ink $69M deal to develop Alzheimer’s drug
Roche’s diabetes app recalled over software bug: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.